Mercer Global Advisors
SKYE icon

Mercer Global Advisors’s Skye Bioscience SKYE Stock Holding History

Mercer Global Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13K Buy
+3,065
New +$2.41K ﹤0.01% 5582

Other funds holding SKYE

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Mercer Global Advisors's SKYE Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Skye Bioscience (SKYE) in Q2 2026: 3,065 shares worth $2.13K. The stake represents ﹤0.01% of the portfolio and ranks #5582 among its holdings.

26 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Mercer Global Advisors held 3,065 shares of Skye Bioscience worth $2.13K as of Q2 2026.
  • Skye Bioscience was a new Mercer Global Advisors position in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5582 holding.
  • 26 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.